French national diagnosis and care protocol (PNDS) for infantile idiopathic hypercalcemia (IIH).

IF 3.6 2区 医学 Q2 GENETICS & HEREDITY
Cyril Amouroux, Valérie Porquet-Bordes, Elodie Adler, Yoan Le Goff, Justine Bacchetta, Jean Philippe Bertocchio, Gilles Cambonie, Marie Courbebaisse, Odile Dicky, Thomas Edouard, Barbara Girerd, Vincent Guigonis, Fairouz Halitim, Pascal Houiller, Agnès Linglart, Emeline Marquant, Denis Morin, Jean Pierre Salles, Anya Rothenbuhler
{"title":"French national diagnosis and care protocol (PNDS) for infantile idiopathic hypercalcemia (IIH).","authors":"Cyril Amouroux, Valérie Porquet-Bordes, Elodie Adler, Yoan Le Goff, Justine Bacchetta, Jean Philippe Bertocchio, Gilles Cambonie, Marie Courbebaisse, Odile Dicky, Thomas Edouard, Barbara Girerd, Vincent Guigonis, Fairouz Halitim, Pascal Houiller, Agnès Linglart, Emeline Marquant, Denis Morin, Jean Pierre Salles, Anya Rothenbuhler","doi":"10.1186/s13023-026-04483-3","DOIUrl":null,"url":null,"abstract":"<p><p>The objective of this study was to establish a French National Diagnosis and Care Protocol (PNDS: Protocole National de Diagnostic et de Soins), with the aim of providing health professionals with free, open access synthesis on optimal management and care of patients with Infantile Idiopathic Hypercalcemia (IIH) ( https://www.has-sante.fr/jcms/p_3522489/fr/hypercalcemie-infantile-idiopathique-hii ). The process involved a critical review of the literature and a multidisciplinary expert consensus. IIH is a rare genetic disorder, with a prevalence estimated at 1 in 33,000. Its clinical manifestations (such as urinary stones or nephrocalcinosis) can appear at different ages. The pathophysiology of IHH is characterized by excessive 1,25(OH)2 vitamin D mediated dietary digestive calcium absorption. The underlying mechanism varies depending on the pathogenic variant involved, which is located in one of two genes, CYP24A1 or SLC34A1. The natural history and pathophysiology of IHH remain poorly understood and are underreported in the literature. Management of the disease varies according to the presentation and severity of hypercalcemia. Non-specific management strategies encompass the cessation of calcium intake, the discontinuation of native vitamin D supplementation, hyperhydration, and the occasional utilization of bisphosphonates. The necessity for long-term treatment, which may encompass both non-specific measures and specific interventions, depends on the severity and the genetic variant identified. Long-term follow-up appears essential, although there is limited data available, particularly for detecting complications of the disease, with nephrocalcinosis being the primary one.</p>","PeriodicalId":19651,"journal":{"name":"Orphanet Journal of Rare Diseases","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13673774/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orphanet Journal of Rare Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13023-026-04483-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

The objective of this study was to establish a French National Diagnosis and Care Protocol (PNDS: Protocole National de Diagnostic et de Soins), with the aim of providing health professionals with free, open access synthesis on optimal management and care of patients with Infantile Idiopathic Hypercalcemia (IIH) ( https://www.has-sante.fr/jcms/p_3522489/fr/hypercalcemie-infantile-idiopathique-hii ). The process involved a critical review of the literature and a multidisciplinary expert consensus. IIH is a rare genetic disorder, with a prevalence estimated at 1 in 33,000. Its clinical manifestations (such as urinary stones or nephrocalcinosis) can appear at different ages. The pathophysiology of IHH is characterized by excessive 1,25(OH)2 vitamin D mediated dietary digestive calcium absorption. The underlying mechanism varies depending on the pathogenic variant involved, which is located in one of two genes, CYP24A1 or SLC34A1. The natural history and pathophysiology of IHH remain poorly understood and are underreported in the literature. Management of the disease varies according to the presentation and severity of hypercalcemia. Non-specific management strategies encompass the cessation of calcium intake, the discontinuation of native vitamin D supplementation, hyperhydration, and the occasional utilization of bisphosphonates. The necessity for long-term treatment, which may encompass both non-specific measures and specific interventions, depends on the severity and the genetic variant identified. Long-term follow-up appears essential, although there is limited data available, particularly for detecting complications of the disease, with nephrocalcinosis being the primary one.

婴儿特发性高钙血症(IIH)的法国国家诊断和护理方案(PNDS)。
本研究的目的是建立法国国家诊断和护理方案(PNDS: Protocole National de Diagnostic et de Soins),目的是为卫生专业人员提供免费、开放获取的关于婴儿特发性高钙血症(IIH)患者最佳管理和护理的综合资料(https://www.has-sante.fr/jcms/p_3522489/fr/hypercalcemie-infantile-idiopathique-hii)。该过程包括对文献的批判性审查和多学科专家的共识。IIH是一种罕见的遗传性疾病,患病率估计为3.3万分之一。其临床表现(如尿路结石或肾钙质沉着症)可在不同年龄出现。IHH的病理生理特征是过量的1,25(OH)2维生素D介导的膳食消化钙吸收。潜在的机制取决于所涉及的致病变异,它位于两个基因CYP24A1或SLC34A1中的一个。IHH的自然历史和病理生理学仍然知之甚少,在文献中被低估。根据高钙血症的表现和严重程度,治疗方法各不相同。非特异性管理策略包括停止钙摄入,停止天然维生素D补充,过度补水,偶尔使用双膦酸盐。长期治疗的必要性,可能包括非特异性措施和特定干预措施,取决于严重程度和确定的遗传变异。长期随访似乎是必要的,尽管现有的数据有限,特别是在检测疾病的并发症方面,肾钙质沉着症是主要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases 医学-医学:研究与实验
CiteScore
6.30
自引率
8.10%
发文量
418
审稿时长
4-8 weeks
期刊介绍: Orphanet Journal of Rare Diseases is an open access, peer-reviewed journal that encompasses all aspects of rare diseases and orphan drugs. The journal publishes high-quality reviews on specific rare diseases. In addition, the journal may consider articles on clinical trial outcome reports, either positive or negative, and articles on public health issues in the field of rare diseases and orphan drugs. The journal does not accept case reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书